Healthcare [ 13/13 ] | Biotechnology [ 127/164 ]
NASDAQ | Common Stock
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.
Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
The company was incorporated in 2015 and is based in Hamilton, Bermuda.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 23, 24 | -0.25 Decreased by -38.89% | -0.16 Decreased by -56.25% |
| Feb 28, 24 | 0.35 Increased by +483.33% | -0.14 Increased by +350.00% |
| Oct 31, 23 | -0.20 Decreased by -106.29% | -0.17 Decreased by -17.65% |
| Jul 25, 23 | 0.21 Increased by +172.41% | -0.17 Increased by +223.53% |
| May 2, 23 | -0.18 Increased by +50.00% | -0.21 Increased by +14.29% |
| Feb 28, 23 | 0.06 Increased by +111.32% | -0.23 Increased by +126.09% |
| Nov 1, 22 | 3.18 Increased by +822.73% | 0.78 Increased by +307.69% |
| Aug 3, 22 | -0.29 Increased by +52.46% | -0.44 Increased by +34.09% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 79.86 M Increased by +65.18% | -17.70 M Decreased by -44.29% | Decreased by -22.17% Increased by +12.65% |
| Dec 31, 23 | 83.39 M Increased by +34.76% | 25.24 M Increased by +465.73% | Increased by +30.26% Increased by +319.80% |
| Sep 30, 23 | 67.05 M Decreased by -32.37% | -13.86 M Decreased by -106.18% | Decreased by -20.66% Decreased by -109.14% |
| Jun 30, 23 | 71.47 M Increased by +164.99% | 14.97 M Increased by +174.93% | Increased by +20.95% Increased by +128.28% |
| Mar 31, 23 | 48.34 M Increased by +50.19% | -12.27 M Increased by +51.33% | Decreased by -25.38% Increased by +67.59% |
| Dec 31, 22 | 61.88 M Increased by +230.14% | 4.46 M Increased by +112.28% | Increased by +7.21% Increased by +103.72% |
| Sep 30, 22 | 99.14 M Increased by +719.64% | 224.09 M Increased by +833.67% | Increased by +226.05% Increased by +189.51% |
| Jun 30, 22 | 26.97 M Increased by +250.10% | -19.98 M Increased by +51.93% | Decreased by -74.08% Increased by +86.27% |